Back to Journals » Journal of Experimental Pharmacology » Volume 7

Aryl hydrocarbon receptor antagonism and its role in rheumatoid arthritis

Authors Nguyen NT, Nakahama T, Nguyen C, Tran TT, Le VS, Chu HH, Kishimoto T

Received 26 July 2015

Accepted for publication 7 October 2015

Published 1 December 2015 Volume 2015:7 Pages 29—35


Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Professor George Taylor

Peer reviewer comments 2

Editor who approved publication: Professor Bal Lokeshwar

Nam Trung Nguyen,1,* Taisuke Nakahama,2,* Chi Hung Nguyen,1 Trang Thu Tran,1 Van Son Le,1 Hoang Ha Chu,1 Tadamitsu Kishimoto3

1National Key Laboratory of Gene Technology, Institute of Biotechnology, Vietnam Academy of Science and Technology, Hanoi, Vietnam; 2Laboratory of RNA Function, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan; 3Laboratory of Immune Regulation, WPI-Immunology Frontier Research Center, Osaka University, Suita, Osaka, Japan

*These authors contributed equally to this work

Abstract: Although rheumatoid arthritis (RA) is the most common autoimmune disease, affecting approximately 1% of the population worldwide, its pathogenic mechanisms are poorly understood. Tobacco smoke, an environmental risk factor for RA, contains several ligands of aryl hydrocarbon receptor (Ahr), also known as dioxin receptor. Ahr plays critical roles in the immune system. We previously demonstrated that Ahr in helper T-cells contributes to development of collagen-induced arthritis, a mouse model of RA. Other studies have shown that cigarette smoke condensate and pure Ahr ligands exacerbate RA by altering bone metabolism and inducing proinflammatory responses in fibroblast-like synoviocytes. Consistent with these findings, several Ahr antagonists such as α-naphthoflavone, resveratrol, and GNF351 reverse the effect of Ahr ligands in RA pathogenesis. In this review, we summarize the current knowledge of Ahr function in the immune system and the potential clinical benefits of Ahr antagonism in treating RA.

Keywords: dioxin receptor, antagonists, autoimmunity

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]